股票代码：300016 股票简称：北陆药业 公告编号：2025-122 1、投资目的 北京北陆药业股份有限公司 关于使用闲置自有资金进行现金管理的公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有 虚假记载、误导性陈述或者重大遗漏。 为进一步提高暂时闲置自有资金的使用效率，获取较好的投资回报，在 不影响公司正常经营、并有效控制风险的前提下，根据《深圳证券交易所创 业板股票上市规则》、《深圳证券交易所上市公司自律监管指引第 2 号—— 创业板上市公司规范运作》等有关法律法规的规定，北京北陆药业股份有限 公司（以下简称"公司"或"北陆药业"）于 2025 年 12 月 18 日召开第九届 董事会第六次会议，审议通过了《关于使用闲置自有资金进行现金管理的议 案》。同意公司使用额度不超过 5 亿元的自有资金进行现金管理，上述额度 自董事会审议通过之日起 12 个月内有效，在上述额度和期限范围内，资金可 以滚动使用。现将具体情况公告如下： 一、本次使用闲置自有资金进行现金管理的基本情况 进一步提高资金使用效率，在确保公司日常运营正常运转的情况下，合 理利用部分暂时闲置自有资金进行现金管理，可以获得一定 ...

股票代码：300016 股票简称：北陆药业 公告编号：2025-121 北京北陆药业股份有限公司 第九届董事会第六次会议决议公告 为进一步提高暂时闲置自有资金的使用效率，获取较好的投资回报，在不 影响公司正常经营、并有效控制风险的前提下，董事会同意使用额度不超过 5 亿元的自有资金进行现金管理，上述额度自董事会审议通过之日起 12 个月内 有效，在上述额度和期限范围内，资金可以滚动使用。 具体内容详见公司于巨潮资讯网（www.cninfo.com.cn）等中国证监会指 定信息披露网站披露的《关于使用闲置自有资金进行现金管理的公告》。 表决结果：9票同意，0票反对，0票弃权。 1 特此公告。 北京北陆药业股份有限公司 董事会 二○二五年十二月十八日 2 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有 虚假记载、误导性陈述或者重大遗漏。 北京北陆药业股份有限公司（以下简称"公司"）第九届董事会第六次 会议于2025年12月18日下午以现场及通讯相结合的方式召开，会议通知以邮 件方式送达各位董事。本次会议应出席董事9人，实际出席董事9人，实际参 加表决董事9人。本次会议的召集召开程序符合《公司法》和 ...

证券日报网讯12月12日晚间，北陆药业（300016）发布公告称，近日公司收到国家药品监督管理局核准 签发的吡格列酮二甲双胍片(15mg/500mg)的《药品注册证书》，按照化学药品3类获批，视同通过仿制 药质量和疗效一致性评价。 ...

Group 1 - Shouyao Holdings is planning to issue H-shares and list on the Hong Kong Stock Exchange, with discussions ongoing with intermediaries regarding the specifics of the listing [1] - Jiangsu Guoxin's subsidiary, Guoxin Mazhou, has completed the trial operation of a 1000MW coal-fired power unit, which is set to officially commence operations on December 12, 2025 [2] - Yuekang Pharmaceutical's mRNA tumor vaccine has received clinical trial approval from the National Medical Products Administration for treating advanced solid tumors [3] Group 2 - Dongli New Science plans to invest 666 million yuan in the restructuring of SAIC Hongyan, acquiring approximately 14.66% equity post-restructuring [4] - Longsheng Technology is set to invest approximately 350 million yuan in the establishment of an intelligent robot innovation center in Wuxi [5] - Shangwei Co. has received a government subsidy of 2.212 million yuan, which accounts for 13.53% of its audited net profit for 2024 [6] Group 3 - Anglikang has received drug registration certificates for Diclofenac Sodium Enteric-Coated Tablets and approval for a supplemental application for Sacubitril/Valsartan Sodium Tablets [7] - Guangzhou Development has received acceptance notices for the registration of 8 billion yuan in medium-term notes and 6 billion yuan in short-term financing bonds [8] - Kebo Da plans to increase capital by 21.2 million euros (approximately 174 million yuan) in its wholly-owned subsidiary in Germany [9][10] Group 4 - Changguang Huaxin has received a total of 11.6672 million yuan in government subsidies, including 8.0552 million yuan related to income [11] - Haizheng Pharmaceutical's subsidiary has received a European Pharmacopoeia suitability certificate for its raw material [12] - Qianjin Pharmaceutical's subsidiary has received a drug registration certificate for Lurasidone Hydrochloride Tablets, used for treating schizophrenia [13] Group 5 - Daimai Co. has received a warning letter from the Shanghai Securities Regulatory Bureau due to failure to timely disclose a significant event related to a fire incident [14] - ST Changyao's subsidiary has recently ceased production due to financial difficulties and competitive pressures in the photovoltaic industry [15] - Guodian Power is investing in the construction of a 2×1000MW expansion project at the Ganbi Power Plant, with a total dynamic investment of 7.218 billion yuan [16] Group 6 - Kaichuang International's subsidiary has completed the handover of a tuna purse seine vessel, expected to be operational by 2026 [16] - Tieke Rail plans to sign an energy management agreement for a distributed photovoltaic project, which is expected to save approximately 1.441 million yuan in electricity costs over 25 years [18] - Bailian Co. plans to sign a land compensation agreement with Friendship Logistics, with a total compensation of 103 million yuan [19] Group 7 - Dayu Water-saving's subsidiary has been pre-awarded two high-standard farmland construction projects, with total expected amounts of 137 million yuan and 135 million yuan respectively [20] - Tianma Technology reported a total eel output of approximately 1197.15 tons in November, with sales prices ranging from 53,000 yuan/ton to 89,000 yuan/ton [21] - Guorui Technology's subsidiary has been shortlisted for the GXLF project with a bid of 76 million yuan [22] Group 8 - Qingdao Food's deputy general manager has resigned for personal reasons [23] - Guosheng Zhike plans to use up to 900 million yuan of idle funds for cash management [24] - Guodian Nanrui plans to use up to 23 billion yuan of idle funds for entrusted wealth management [25] Group 9 - Jiahuan Energy plans to merge its wholly-owned subsidiary, Zhejiang Jiahuan Hydrogen Peroxide Co., Ltd., through an overall absorption merger [26] - Ganyue Expressway reported vehicle toll service revenue of 309 million yuan for November [27] - Jinling Hotel's chairman has resigned due to work changes [28] Group 10 - Lisheng Pharmaceutical's subsidiary has received drug registration certificates for Apremilast Tablets [29] - Baotai has received a positive opinion from the European Medicines Agency for Gotenfia® for various inflammatory conditions [30] - ST Zhisheng has been awarded a smart city governance project with a bid amount of 104 million yuan [31] Group 11 - Chenxi Aviation and its related personnel have received administrative regulatory measures from the Shaanxi Securities Regulatory Bureau due to financial reporting issues [32] - Portong Medical has appointed Xia Canglan as the new deputy general manager [33] - Maide Medical plans to repurchase shares with a total amount between 20 million and 40 million yuan [34] Group 12 - Jimin Health plans to establish a joint venture with a total investment of 600 million yuan, focusing on AI and software development [35] - Beilu Pharmaceutical has received a drug registration certificate for Pioglitazone Metformin Tablets [36] - Hainan Mining plans to entrust the overall management of the Shiluo Iron Mine to a construction company for three years, with a total contract amount of approximately 818 million yuan [38] Group 13 - Huiyu Pharmaceutical has received a drug registration certificate for Nicardipine Hydrochloride Injection [39] - Baoland has received a government subsidy of 10 million yuan related to income [40] - Qingdao Port has terminated the acquisition of 100% equity in an oil company and 50% equity in Rizhao Shihua due to regulatory concerns [41]

（原标题：北陆药业(300016.SZ)：获得吡格列酮二甲双胍片《药品注册证书》） 格隆汇12月12日丨北陆药业(300016.SZ)公布，收到国家药品监督管理局核准签发的吡格列酮二甲双胍 片（15mg/500mg）的《药品注册证书》。吡格列酮二甲双胍片（15mg/500mg）的原研企业是武田药品 工业株式会社，2005年8月获美国批准上市。目前，原研厂家的吡格列酮二甲双胍片尚未在中国上市。 本品适用于在饮食控制和运动的基础上，用于目前使用盐酸吡格列酮和盐酸二甲双胍联合治疗的2型糖 尿病患者或单用盐酸二甲双胍治疗后血糖控制不佳的2型糖尿病患者。 ...

Core Viewpoint - The company has received approval from the National Medical Products Administration for the drug Pioglitazone Metformin Tablets (15mg/500mg), enhancing its diabetes medication product line and market competitiveness [1] Group 1: Product Approval - The Pioglitazone Metformin Tablets (15mg/500mg) have been approved as a Class 3 chemical drug, indicating it has passed the consistency evaluation for generic drug quality and efficacy [1] - This approval allows the company to expand its diabetes treatment offerings, which is expected to strengthen its position in the market [1] Group 2: Market Strategy - The company plans to actively prepare for the launch of the new product and aims to bring it to market as soon as possible [1] - There may be uncertainties affecting the production and sales of the new product, which the company will need to navigate [1]

格隆汇12月12日丨北陆药业(300016.SZ)公布，收到国家药品监督管理局核准签发的吡格列酮二甲双胍 片（15mg/500mg）的《药品注册证书》。吡格列酮二甲双胍片（15mg/500mg）的原研企业是武田药品 工业株式会社，2005年8月获美国批准上市。目前，原研厂家的吡格列酮二甲双胍片尚未在中国上市。 本品适用于在饮食控制和运动的基础上，用于目前使用盐酸吡格列酮和盐酸二甲双胍联合治疗的2型糖 尿病患者或单用盐酸二甲双胍治疗后血糖控制不佳的2型糖尿病患者。 ...

北陆药业（300016）(300016.SZ)公告，公司收到国家药品监督管理局核准签发的吡格列酮二甲双胍片 (15mg/500mg)的《药品注册证书》。本品适用于在饮食控制和运动的基础上，用于目前使用盐酸吡格列 酮和盐酸二甲双胍联合治疗的2型糖尿病患者或单用盐酸二甲双胍治疗后血糖控制不佳的2型糖尿病患 者。 ...

北陆药业公告，近日收到国家药品监督管理局核准签发的吡格列酮二甲双胍片（15mg/500mg）的《药 品注册证书》。该药品适用于在饮食控制和运动的基础上，用于目前使用盐酸吡格列酮和盐酸二甲双胍 联合治疗的2型糖尿病患者或单用盐酸二甲双胍治疗后血糖控制不佳的2型糖尿病患者。根据米内网数据 显示，2024年中国三大终端六大市场吡格列酮二甲双胍片的销售额约为16.74亿元，其中城市公立医院 和县级公立医院销售额为11.83亿元，城市社区中心和乡镇卫生院销售额为1.95亿元，城市实体药店和网 上药店销售额为2.96亿元。 ...

智通财经APP讯，北陆药业(300016.SZ)公告，公司收到国家药品监督管理局核准签发的吡格列酮二甲双 胍片(15mg/500mg)的《药品注册证书》。本品适用于在饮食控制和运动的基础上，用于目前使用盐酸吡 格列酮和盐酸二甲双胍联合治疗的2型糖尿病患者或单用盐酸二甲双胍治疗后血糖控制不佳的2型糖尿病 患者。 ...